On Thursday, the Multidisciplinary Association for Psychedelic Studies (“MAPS”) reported it had collected $30 million in donations, which will be used in the completion of a study on the use of MDMA to help remedy PTSD, or post-traumatic stress disorder.
MAPS stated that the funds would be used in the MDMA trials, which is a Phase 3 study, in a bid to secure approval from the FDA. The FDA had before identified MDMA, commonly referred to as ecstasy, as “breakthrough therapy” using earlier trials as their basis.
In total, an estimated 2,500 individuals donated to help MAPS get to their fundraising objective in six months. Tim Ferriss, an author, podcaster and tech investor, contributed significantly to the success of the fundraising campaign, as he helped secure philanthropic contributions worth $10 million.
MAPS hopes to be given FDA approval by the year 2022.
Rick Doblin, the founder of MAPS, stated that decriminalization efforts helped to destigmatize as well as make the study and research easier and more comfortable while helping people feel more at ease with looking into therapy with psychedelics as an option for treatment.
He also notes that the decriminalization movement took place only after they had made significant progress in their research. The movement changed peoples’ perspectives and attitudes towards MDMA.
The Multidisciplinary Association for Psychedelic Studies had partnered with the Psychedelic Science Funders Collaborative on the fundraising initiative.
The cofounder of Psychedelic Science Funders Collaborative, Joe Green, stated that the study would be a breakthrough for psychedelic medicine generally, which would lead to more understanding about psychedelic therapy, potentially helping treat a lot of the existing mental health disorders.
Additionally, other studies that show therapeutic potential helped expand psychedelics access. For instance, a scientific study that was published in 2019 discussed psychotherapy using MDMA and its various benefits.
A report was released earlier in the year, from a government commission that was tasked with expanding recommendations on how to better mental health treatments for veterans. The report advised the Executive and Congress to encourage further research of the therapeutic possibilities of marijuana as well as psychedelics such as MDMA and psilocybin mushrooms.
Additionally, a proposal to decriminalize an extensive variety of psychedelics has formally qualified for the November ballot in Washington, D.C.
Also, the health minister for Canada recently gave 4 cancer patients an exemption that allowed them to legally utilize psilocybin for supportive care. All these developments give sector players like Cybin Corp. a lot of encouragement regarding the future of the industry.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
